IP Library Granted Patent US 9,040,662
Granted Patent B2
US 9,040,662 · App. 14/240,801 · Granted May 26, 2015

Methods and compositions comprising a C-terminal Bax peptide

Inventors: Annette Khaled (Orlando, FL); Rebecca Boohaker (Orlando, FL); Michael Lee (Orlando, FL); Jesus Perez Figueroa (Orlando, FL)
Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION
C07K7/08A61K38/1761A61K9/5153A61K38/16A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,662
App. No.
14/240,801
Granted
May 26, 2015
Kind
B2
Abstract

In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.

Claims (18)

1. A method of permeabilizing membranes of cells, comprising, administering to the cell an effective amount of a) a C-terminal B cell lymphoma-2 (Bcl-2)-associated X protein (Bax) peptide (CT20p peptide), wherein the CT20p peptide comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a combination of two or more of SEQ ID NOs: 1-4, or b) a composition comprising a CT20p peptide, wherein the composition comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a combination of two or more of SEQ ID NOs: 1-4.

2. The method of claim 1 , further comprising repeating the administration of the CT20p peptide or the composition comprising the CT20p peptide.

3. The method of claim 1 , comprising administering the CT20p peptide or CT20p peptide composition directly into a tumor cell.

4. The method of claim 1 , further comprising inducing cell death.

5. The method of claim 4 , wherein the cell death occurs independently of endogenous Bax activity, or endogenous caspase activity, or both.

6. The method of claim 4 , wherein the cell death is resistant to B cell lymphoma-2 (Bcl-2) over-expression.

7. The method of claim 1 , wherein the CT20p peptide is encapsulated in polymeric nanoparticles.

8. The method of claim 7 , wherein the nanoparticles are aminated.

9. The method of claim 7 , wherein the nanoparticles are carboxylated.

10. The method of claim 1 , further comprising administering to the cell one or more therapeutic agents.

11. The method of claim 1 , wherein the cell is a cancer cell.

12. The method of claim 11 , wherein the cancer cell is a breast cancer cell, colorectal cancer cell, or lung cancer cell, or wherein the cancer cell is a drug resistant cancer cell.

13. The method of claim 1 , wherein the membrane is a mitochondrial membrane.

14. A composition for permeabilizing membranes in cells, comprising, a CT20p peptide, wherein the CT20p peptide comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a combination of two or more of SEQ ID NOs: 1-4.

15. The composition of claim 14 , wherein the CT20p peptide is encapsulated in polymeric nanoparticles.

16. The composition of claim 15 , wherein the nanoparticles are aminated.

17. The composition of claim 15 , wherein the nanoparticles are carboxylated.

18. The composition of claim 14 , further comprising one or more therapeutic agents.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: BOOHAKER, REBECCA
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 035767/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2015
From: KHALED, ANNETTE; LEE, MICHAEL; FIGUEROA, JESUS PEREZ
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 035449/0923 →
CONFIRMATORY LICENSE Recorded Feb 10, 2015
From: UNIVERSITY OF CENTRAL FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034926/0625 →
Continuity (3)
Provisional Application 61527524 · Aug 25, 2011
Provisional Application 61645891 · May 11, 2012
Related Publication 20140255299A1 · Sep 11, 2014